Your browser doesn't support javascript.
loading
Montrer: 20 | 50 | 100
Résultats 1 - 20 de 22
Filtrer
1.
J Cell Sci ; 135(8)2022 04 15.
Article de Anglais | MEDLINE | ID: mdl-35302162

RÉSUMÉ

SMAD2, an effector of the NODAL/Activin signalling pathway, regulates developmental processes by sensing distinct chromatin states and interacting with different transcriptional partners. However, the network of factors that controls SMAD2 chromatin binding and shapes its transcriptional programme over time is poorly characterised. Here, we combine ATAC-seq with computational footprinting to identify temporal changes in chromatin accessibility and transcription factor activity upon NODAL/Activin signalling. We show that SMAD2 binding induces chromatin opening genome wide. We discover footprints for FOXI3, FOXO3 and ZIC3 at the SMAD2-bound enhancers of the early response genes, Pmepa1 and Wnt3, respectively, and demonstrate their functionality. Finally, we determine a mechanism by which NODAL/Activin signalling induces delayed gene expression, by uncovering a self-enabling transcriptional cascade whereby activated SMADs, together with ZIC3, induce the expression of Wnt3. The resultant activated WNT pathway then acts together with the NODAL/Activin pathway to regulate expression of delayed target genes in prolonged NODAL/Activin signalling conditions. This article has an associated First Person interview with the first author of the paper.


Sujet(s)
Activines , Facteurs de transcription , Activines/métabolisme , Chromatine/génétique , Régulation de l'expression des gènes au cours du développement , Humains , Protéines membranaires/métabolisme , Protéine Nodal/métabolisme , Protéine Smad2 , Facteurs de transcription/génétique , Facteurs de transcription/métabolisme , Facteur de croissance transformant bêta/métabolisme
3.
Nat Commun ; 12(1): 6374, 2021 11 04.
Article de Anglais | MEDLINE | ID: mdl-34737283

RÉSUMÉ

The transcriptional effector SMAD4 is a core component of the TGF-ß family signaling pathways. However, its role in vertebrate embryo development remains unresolved. To address this, we deleted Smad4 in zebrafish and investigated the consequences of this on signaling by the TGF-ß family morphogens, BMPs and Nodal. We demonstrate that in the absence of Smad4, dorsal/ventral embryo patterning is disrupted due to the loss of BMP signaling. However, unexpectedly, Nodal signaling is maintained, but lacks robustness. This Smad4-independent Nodal signaling is sufficient for mesoderm specification, but not for optimal endoderm specification. Furthermore, using Optical Projection Tomography in combination with 3D embryo morphometry, we have generated a BMP morphospace and demonstrate that Smad4 mutants are morphologically indistinguishable from embryos in which BMP signaling has been genetically/pharmacologically perturbed. Smad4 is thus differentially required for signaling by different TGF-ß family ligands, which has implications for diseases where Smad4 is mutated or deleted.


Sujet(s)
Protéines morphogénétiques osseuses/métabolisme , Protéine Nodal/métabolisme , Protéine Smad-4/métabolisme , Facteur de croissance transformant bêta/métabolisme , Protéines de poisson-zèbre/métabolisme , Danio zébré/croissance et développement , Animaux , Développement embryonnaire , Endoderme/métabolisme , Techniques de knock-out de gènes , Mésoderme/métabolisme , Morphogenèse , Transduction du signal , Protéine Smad-4/déficit , Protéine Smad-4/génétique , Danio zébré/embryologie , Danio zébré/génétique , Danio zébré/métabolisme , Protéines de poisson-zèbre/déficit , Protéines de poisson-zèbre/génétique
4.
EMBO J ; 40(14): e106317, 2021 07 15.
Article de Anglais | MEDLINE | ID: mdl-34003511

RÉSUMÉ

Fibrodysplasia ossificans progressiva (FOP) and diffuse intrinsic pontine glioma (DIPG) are debilitating diseases that share causal mutations in ACVR1, a TGF-ß family type I receptor. ACVR1R206H is a frequent mutation in both diseases. Pathogenic signaling via the SMAD1/5 pathway is mediated by Activin A, but how the mutation triggers aberrant signaling is not known. We show that ACVR1 is essential for Activin A-mediated SMAD1/5 phosphorylation and is activated by two distinct mechanisms. Wild-type ACVR1 is activated by the Activin type I receptors, ACVR1B/C. In contrast, ACVR1R206H activation does not require upstream kinases, but is predominantly activated via Activin A-dependent receptor clustering, which induces its auto-activation. We use optogenetics and live-imaging approaches to demonstrate Activin A-induced receptor clustering and show it requires the type II receptors ACVR2A/B. Our data provide molecular mechanistic insight into the pathogenesis of FOP and DIPG by linking the causal activating genetic mutation to disrupted signaling.


Sujet(s)
Récepteur activine, type 1/génétique , Récepteur activine, type 1/métabolisme , Activines/génétique , Activines/métabolisme , Phosphorylation/génétique , Animaux , Lignée cellulaire , Analyse de regroupements , Cellules HEK293 , Humains , Souris , Mutation/génétique , Myosite ossifiante/génétique , Cellules NIH 3T3 , Transduction du signal/génétique
5.
Elife ; 102021 01 08.
Article de Anglais | MEDLINE | ID: mdl-33416497

RÉSUMÉ

Shprintzen-Goldberg syndrome (SGS) is a multisystemic connective tissue disorder, with considerable clinical overlap with Marfan and Loeys-Dietz syndromes. These syndromes have commonly been associated with enhanced TGF-ß signaling. In SGS patients, heterozygous point mutations have been mapped to the transcriptional co-repressor SKI, which is a negative regulator of TGF-ß signaling that is rapidly degraded upon ligand stimulation. The molecular consequences of these mutations, however, are not understood. Here we use a combination of structural biology, genome editing, and biochemistry to show that SGS mutations in SKI abolish its binding to phosphorylated SMAD2 and SMAD3. This results in stabilization of SKI and consequently attenuation of TGF-ß responses, both in knockin cells expressing an SGS mutation and in fibroblasts from SGS patients. Thus, we reveal that SGS is associated with an attenuation of TGF-ß-induced transcriptional responses, and not enhancement, which has important implications for other Marfan-related syndromes.


Sujet(s)
Arachnodactylie/génétique , Craniosynostoses/génétique , Protéines de liaison à l'ADN/génétique , Syndrome de Marfan/génétique , Mutation , Protéines proto-oncogènes/génétique , Facteur de croissance transformant bêta/génétique , Protéines de liaison à l'ADN/métabolisme , Femelle , Humains , Mâle , Protéines proto-oncogènes/métabolisme , Transduction du signal , Facteur de croissance transformant bêta/métabolisme
6.
Cell Death Dis ; 11(1): 49, 2020 01 22.
Article de Anglais | MEDLINE | ID: mdl-31969556

RÉSUMÉ

The signalling pathways initiated by members of the transforming growth factor-ß (TGFß) family of cytokines control many metazoan cellular processes, including proliferation and differentiation, epithelial-mesenchymal transition (EMT) and apoptosis. TGFß signalling is therefore strictly regulated to ensure appropriate context-dependent physiological responses. In an attempt to identify novel regulatory components of the TGFß signalling pathway, we performed a pharmacological screen by using a cell line engineered to report the endogenous transcription of the TGFß-responsive target gene PAI-1. The screen revealed that small molecule inhibitors of salt-inducible kinases (SIKs) attenuate TGFß-mediated transcription of PAI-1 without affecting receptor-mediated SMAD phosphorylation, SMAD complex formation or nuclear translocation. We provide evidence that genetic inactivation of SIK isoforms also attenuates TGFß-dependent transcriptional responses. Pharmacological inhibition of SIKs by using multiple small-molecule inhibitors potentiated apoptotic cell death induced by TGFß stimulation. Our data therefore provide evidence for a novel function of SIKs in modulating TGFß-mediated transcriptional and cellular responses.


Sujet(s)
Apoptose/génétique , Inhibiteurs de protéines kinases/pharmacologie , Protein kinases/métabolisme , Protein-Serine-Threonine Kinases/métabolisme , Serpine E2/métabolisme , Facteur de croissance transformant bêta/pharmacologie , Animaux , Apoptose/effets des médicaments et des substances chimiques , Lignée cellulaire tumorale , Noyau de la cellule/effets des médicaments et des substances chimiques , Noyau de la cellule/génétique , Noyau de la cellule/métabolisme , Cytoplasme/effets des médicaments et des substances chimiques , Cytoplasme/génétique , Cytoplasme/métabolisme , Techniques de knock-out de gènes , Extinction de l'expression des gènes , Humains , Indanes/pharmacologie , Souris , Souris de lignée C57BL , Phosphorylation , Isoformes de protéines/génétique , Isoformes de protéines/métabolisme , Protein kinases/génétique , Protein-Serine-Threonine Kinases/génétique , Pyrimidines/pharmacologie , Serpine E2/génétique , Transduction du signal/effets des médicaments et des substances chimiques , Transduction du signal/génétique , Protéines Smad/métabolisme
7.
Nat Commun ; 10(1): 4958, 2019 10 31.
Article de Anglais | MEDLINE | ID: mdl-31673008

RÉSUMÉ

Altered structural brain asymmetry in autism spectrum disorder (ASD) has been reported. However, findings have been inconsistent, likely due to limited sample sizes. Here we investigated 1,774 individuals with ASD and 1,809 controls, from 54 independent data sets of the ENIGMA consortium. ASD was significantly associated with alterations of cortical thickness asymmetry in mostly medial frontal, orbitofrontal, cingulate and inferior temporal areas, and also with asymmetry of orbitofrontal surface area. These differences generally involved reduced asymmetry in individuals with ASD compared to controls. Furthermore, putamen volume asymmetry was significantly increased in ASD. The largest case-control effect size was Cohen's d = -0.13, for asymmetry of superior frontal cortical thickness. Most effects did not depend on age, sex, IQ, severity or medication use. Altered lateralized neurodevelopment may therefore be a feature of ASD, affecting widespread brain regions with diverse functions. Large-scale analysis was necessary to quantify subtle alterations of brain structural asymmetry in ASD.


Sujet(s)
Trouble du spectre autistique/imagerie diagnostique , Cortex cérébral/imagerie diagnostique , Adolescent , Adulte , Trouble du spectre autistique/anatomopathologie , Encéphale/imagerie diagnostique , Encéphale/anatomopathologie , Études cas-témoins , Cortex cérébral/anatomopathologie , Enfant , Femelle , Lobe frontal/imagerie diagnostique , Lobe frontal/anatomopathologie , Gyrus du cingulum/imagerie diagnostique , Gyrus du cingulum/anatomopathologie , Humains , Imagerie par résonance magnétique , Mâle , Adulte d'âge moyen , Taille d'organe , Cortex préfrontal/imagerie diagnostique , Cortex préfrontal/anatomopathologie , Lobe temporal/imagerie diagnostique , Lobe temporal/anatomopathologie , Jeune adulte
8.
Cell Rep ; 25(7): 1841-1855.e5, 2018 11 13.
Article de Anglais | MEDLINE | ID: mdl-30428352

RÉSUMÉ

Signal transduction pathways stimulated by secreted growth factors are tightly regulated at multiple levels between the cell surface and the nucleus. The trafficking of cell surface receptors is emerging as a key step for regulating appropriate cellular responses, with perturbations in this process contributing to human diseases, including cancer. For receptors recognizing ligands of the transforming growth factor ß (TGF-ß) family, little is known about how trafficking is regulated or how this shapes signaling dynamics. Here, using whole genome small interfering RNA (siRNA) screens, we have identified the ESCRT (endosomal sorting complex required for transport) machinery as a crucial determinant of signal duration. Downregulation of ESCRT components increases the outputs of TGF-ß signaling and sensitizes cells to low doses of ligand in their microenvironment. This sensitization drives an epithelial-to-mesenchymal transition (EMT) in response to low doses of ligand, and we demonstrate a link between downregulation of the ESCRT machinery and cancer survival.


Sujet(s)
Complexes de tri endosomique requis pour le transport/métabolisme , Récepteurs TGF-bêta/métabolisme , Transduction du signal , Facteur de croissance transformant bêta/métabolisme , Activines/métabolisme , Animaux , Protéines morphogénétiques osseuses/métabolisme , Lignée cellulaire , Régulation négative , Transition épithélio-mésenchymateuse , Génome humain , Humains , Lysosomes/métabolisme , Souris , Corps multivésiculaires/métabolisme , Tumeurs/anatomopathologie , Phosphorylation , Pronostic , Transport des protéines , Protéolyse , Protéine Smad2/métabolisme , Analyse de survie , Ubiquitin-protein ligases/métabolisme , Régulation positive
9.
Am J Psychiatry ; 175(4): 359-369, 2018 04 01.
Article de Anglais | MEDLINE | ID: mdl-29145754

RÉSUMÉ

OBJECTIVE: Neuroimaging studies show structural differences in both cortical and subcortical brain regions in children and adults with autism spectrum disorder (ASD) compared with healthy subjects. Findings are inconsistent, however, and it is unclear how differences develop across the lifespan. The authors investigated brain morphometry differences between individuals with ASD and healthy subjects, cross-sectionally across the lifespan, in a large multinational sample from the Enhancing Neuroimaging Genetics Through Meta-Analysis (ENIGMA) ASD working group. METHOD: The sample comprised 1,571 patients with ASD and 1,651 healthy control subjects (age range, 2-64 years) from 49 participating sites. MRI scans were preprocessed at individual sites with a harmonized protocol based on a validated automated-segmentation software program. Mega-analyses were used to test for case-control differences in subcortical volumes, cortical thickness, and surface area. Development of brain morphometry over the lifespan was modeled using a fractional polynomial approach. RESULTS: The case-control mega-analysis demonstrated that ASD was associated with smaller subcortical volumes of the pallidum, putamen, amygdala, and nucleus accumbens (effect sizes [Cohen's d], 0.13 to -0.13), as well as increased cortical thickness in the frontal cortex and decreased thickness in the temporal cortex (effect sizes, -0.21 to 0.20). Analyses of age effects indicate that the development of cortical thickness is altered in ASD, with the largest differences occurring around adolescence. No age-by-ASD interactions were observed in the subcortical partitions. CONCLUSIONS: The ENIGMA ASD working group provides the largest study of brain morphometry differences in ASD to date, using a well-established, validated, publicly available analysis pipeline. ASD patients showed altered morphometry in the cognitive and affective parts of the striatum, frontal cortex, and temporal cortex. Complex developmental trajectories were observed for the different regions, with a developmental peak around adolescence. These findings suggest an interplay in the abnormal development of the striatal, frontal, and temporal regions in ASD across the lifespan.


Sujet(s)
Trouble du spectre autistique/imagerie diagnostique , Encéphale/imagerie diagnostique , Cortex cérébral/imagerie diagnostique , Interprétation d'images assistée par ordinateur , Imagerie par résonance magnétique , Adolescent , Adulte , Facteurs âges , Études cas-témoins , Enfant , Enfant d'âge préscolaire , Femelle , Humains , Mâle , Adulte d'âge moyen , Valeurs de référence , Jeune adulte
10.
Front Neurosci ; 10: 306, 2016.
Article de Anglais | MEDLINE | ID: mdl-27445675

RÉSUMÉ

The identification of reliable brain endophenotypes of autism spectrum disorders (ASD) has been hampered to date by the heterogeneity in the neuroanatomical abnormalities detected in this condition. To handle the complexity of neuroimaging data and to convert brain images in informative biomarkers of pathology, multivariate analysis techniques based on Support Vector Machines (SVM) have been widely used in several disease conditions. They are usually trained to distinguish patients from healthy control subjects by making a binary classification. Here, we propose the use of the One-Class Classification (OCC) or Data Description method that, in contrast to two-class classification, is based on a description of one class of objects only. This approach, by defining a multivariate normative rule on one class of subjects, allows recognizing examples from a different category as outliers. We applied the OCC to 314 regional features extracted from brain structural Magnetic Resonance Imaging (MRI) scans of young children with ASD (21 males and 20 females) and control subjects (20 males and 20 females), matched on age [range: 22-72 months of age; mean = 49 months] and non-verbal intelligence quotient (NVIQ) [range: 31-123; mean = 73]. We demonstrated that a common pattern of features characterize the ASD population. The OCC SVM trained on the group of ASD subjects showed the following performances in the ASD vs. controls separation: the area under the receiver operating characteristic curve (AUC) was 0.74 for the male and 0.68 for the female population, respectively. Notably, the ASD vs. controls discrimination results were maximized when evaluated on the subsamples of subjects with NVIQ ≥ 70, leading to AUC = 0.81 for the male and AUC = 0.72 for the female populations, respectively. Language regions and regions from the default mode network-posterior cingulate cortex, pars opercularis and pars triangularis of the inferior frontal gyrus, and transverse temporal gyrus-contributed most to distinguishing individuals with ASD from controls, arguing for the crucial role of these areas in the ASD pathophysiology. The observed brain patterns associate preschoolers with ASD independently of their age, gender and NVIQ and therefore they are expected to constitute part of the ASD brain endophenotype.

11.
Cell Rep ; 15(7): 1597-1610, 2016 05 17.
Article de Anglais | MEDLINE | ID: mdl-27184836

RÉSUMÉ

In order to facilitate the identification of factors and pathways in the cellular response to UV-induced DNA damage, several descriptive proteomic screens and a functional genomics screen were performed in parallel. Numerous factors could be identified with high confidence when the screen results were superimposed and interpreted together, incorporating biological knowledge. A searchable database, bioLOGIC, which provides access to relevant information about a protein or process of interest, was established to host the results and facilitate data mining. Besides uncovering roles in the DNA damage response for numerous proteins and complexes, including Integrator, Cohesin, PHF3, ASC-1, SCAF4, SCAF8, and SCAF11, we uncovered a role for the poorly studied, melanoma-associated serine/threonine kinase 19 (STK19). Besides effectively uncovering relevant factors, the multiomic approach also provides a systems-wide overview of the diverse cellular processes connected to the transcription-related DNA damage response.


Sujet(s)
Altération de l'ADN/effets des radiations , Protéomique , Rayons ultraviolets , Chromatine/métabolisme , Bases de données factuelles , Cellules HEK293 , Humains , Internet , Leupeptines/pharmacologie , Voies et réseaux métaboliques/effets des médicaments et des substances chimiques , Voies et réseaux métaboliques/effets des radiations , Protéines nucléaires/métabolisme , Phosphorylation/effets des radiations , Protein-Serine-Threonine Kinases/métabolisme , Protéome/effets des médicaments et des substances chimiques , Protéome/effets des radiations , RNA polymerase II/métabolisme , Petit ARN interférent/métabolisme , Transcription génétique/effets des radiations , Ubiquitination/effets des radiations , Interface utilisateur
12.
J Neuroimaging ; 25(6): 866-74, 2015.
Article de Anglais | MEDLINE | ID: mdl-26214066

RÉSUMÉ

BACKGROUND AND PURPOSE: Sophisticated algorithms to infer disease diagnosis, pathology progression and patient outcome are increasingly being developed to analyze brain MRI data. They have been successfully implemented in a variety of diseases and are currently investigated in the field of neuropsychiatric disorders, including autism spectrum disorder (ASD). We aim to test the ability to predict ASD from subtle morphological changes in structural magnetic resonance imaging (sMRI). METHODS: The analysis of sMRI of a cohort of male ASD children and controls matched for age and nonverbal intelligence quotient (NVIQ) has been carried out with two widely used preprocessing software packages (SPM and Freesurfer) to extract brain morphometric information at different spatial scales. Then, support vector machines have been implemented to classify the brain features and to localize which brain regions contribute most to the ASD-control separation. RESULTS: The features extracted from the gray matter subregions provide the best classification performance, reaching an area under the receiver operating characteristic curve (AUC) of 74%. This value is enhanced to 80% when considering only subjects with NVIQ over 70. CONCLUSIONS: Despite the subtle impact of ASD on brain morphology and a limited cohort size, results from sMRI-based classifiers suggest a consistent network of altered brain regions.


Sujet(s)
Trouble du spectre autistique/imagerie diagnostique , Encéphale/imagerie diagnostique , Substance grise/imagerie diagnostique , Imagerie par résonance magnétique , Trouble du spectre autistique/anatomopathologie , Encéphale/anatomopathologie , Cartographie cérébrale/méthodes , Enfant d'âge préscolaire , Substance grise/anatomopathologie , Humains , Mâle , Taille d'organe
13.
Article de Anglais | MEDLINE | ID: mdl-26779118

RÉSUMÉ

Endometriosis affects approximately 10% of women of reproductive age. This chronic, gynecological inflammatory disease results in a decreased quality of life for patients, with the main symptoms including chronic pelvic pain and infertility. The steroid hormone 17-ß Estradiol (E2) plays a key role in the pathology. Our previous studies showed that the anti-inflammatory lipid Lipoxin A4 (LXA4) acts as an estrogen receptor-alpha agonist in endometrial epithelial cells, inhibiting certain E2-mediated effects. LXA4 also prevents the progression of endometriosis in a mouse model via anti-proliferative mechanisms and by impacting mediators downstream of ER signaling. The aim of the present study was therefore to examine global proteomic changes evoked by E2 and LXA4 in endometriotic epithelial cells. E2 impacted a greater number of proteins in endometriotic epithelial cells than LXA4. Interestingly, the combination of E2 and LXA4 resulted in a reduced number of regulated proteins, with LXA4 mediating a suppressive effect on E2-mediated signaling. These proteins are involved in diverse pathways of relevance to endometriosis pathology and metabolism, including mRNA translation, growth, proliferation, proteolysis, and immune responses. In summary, this study sheds light on novel pathways involved in endometriosis pathology and further understanding of signaling pathways activated by estrogenic molecules in endometriotic epithelial cells.

14.
PLoS One ; 9(2): e89742, 2014.
Article de Anglais | MEDLINE | ID: mdl-24587003

RÉSUMÉ

Endometriosis, a leading cause of pelvic pain and infertility, is characterized by ectopic growth of endometrial-like tissue and affects approximately 176 million women worldwide. The pathophysiology involves inflammatory and angiogenic mediators as well as estrogen-mediated signaling and novel, improved therapeutics targeting these pathways are necessary. The aim of this study was to investigate mechanisms leading to the establishment and progression of endometriosis as well as the effect of local treatment with Lipoxin A4 (LXA4), an anti-inflammatory and pro-resolving lipid mediator that we have recently characterized as an estrogen receptor agonist. LXA4 treatment significantly reduced endometriotic lesion size and downregulated the pro-inflammatory cytokines IL-1ß and IL-6, as well as the angiogenic factor VEGF. LXA4 also inhibited COX-2 expression in both endometriotic lesions and peritoneal fluid cells, resulting in attenuated peritoneal fluid Prostaglandin E2 (PGE2) levels. Besides its anti-inflammatory effects, LXA4 differentially regulated the expression and activity of the matrix remodeling enzyme matrix metalloproteinase (MMP)-9 as well as modulating transforming growth factor (TGF)-ß isoform expression within endometriotic lesions and in peritoneal fluid cells. We also report for first time that LXA4 attenuated aromatase expression, estrogen signaling and estrogen-regulated genes implicated in cellular proliferation in a mouse model of disease. These effects were observed both when LXA4 was administered prior to disease induction and during established disease. Collectively, our findings highlight potential targets for the treatment of endometriosis and suggest a pleotropic effect of LXA4 on disease progression, by attenuating pro-inflammatory and angiogenic mediators, matrix remodeling enzymes, estrogen metabolism and signaling, as well as downstream proliferative pathways.


Sujet(s)
Voies de biosynthèse/effets des médicaments et des substances chimiques , Dinoprostone/biosynthèse , Endométriose/prévention et contrôle , Oestrogènes/métabolisme , Lipoxines/pharmacologie , Transduction du signal/effets des médicaments et des substances chimiques , Analyse de variance , Animaux , Aromatase/métabolisme , Cyclooxygenase 2/métabolisme , Amorces ADN/génétique , Endométriose/physiopathologie , Femelle , Immunohistochimie , Interleukine-1 bêta/métabolisme , Interleukine-6/métabolisme , Souris , Souris de lignée C57BL , Réaction de polymérisation en chaine en temps réel , Facteur de croissance endothéliale vasculaire de type A/métabolisme
15.
Sci Signal ; 6(305): ra106, 2013 Dec 10.
Article de Anglais | MEDLINE | ID: mdl-24327760

RÉSUMÉ

Understanding the complex dynamics of growth factor signaling requires both mechanistic and kinetic information. Although signaling dynamics have been studied for pathways downstream of receptor tyrosine kinases and G protein (heterotrimeric guanine nucleotide-binding protein)-coupled receptors, they have not been investigated for the transforming growth factor-ß (TGF-ß) superfamily pathways. Using an integrative experimental and mathematical modeling approach, we dissected the dynamic behavior of the TGF-ß to Smad pathway, which is mediated by type I and type II receptor serine/threonine kinases, in response to acute, chronic, and repeated ligand stimulations. TGF-ß exposure produced a transient response that attenuated over time, resulting in desensitized cells that were refractory to further acute stimulation. This loss of signaling competence depended on ligand binding, but not on receptor activity, and was restored only after the ligand had been depleted. Furthermore, TGF-ß binding triggered the rapid depletion of signaling-competent receptors from the cell surface, with the type I and type II receptors exhibiting different degradation and trafficking kinetics. A computational model of TGF-ß signal transduction from the membrane to the nucleus that incorporates our experimental findings predicts that autocrine signaling, such as that associated with tumorigenesis, severely compromises the TGF-ß response, which we confirmed experimentally. Thus, we have shown that the long-term signaling behavior of the TGF-ß pathway is determined by receptor dynamics, does not require TGF-ß-induced gene expression, and influences context-dependent responses in vivo.


Sujet(s)
Protein-Serine-Threonine Kinases/métabolisme , Récepteurs TGF-bêta/métabolisme , Transduction du signal/physiologie , Facteur de croissance transformant bêta-1/métabolisme , Technique de Western , Lignée cellulaire , Membrane cellulaire/métabolisme , Noyau de la cellule/métabolisme , Humains , Kératinocytes/cytologie , Kératinocytes/effets des médicaments et des substances chimiques , Kératinocytes/métabolisme , Cinétique , Ligands , Modèles biologiques , Phosphorylation , Liaison aux protéines , Transport des protéines/effets des médicaments et des substances chimiques , Récepteur de type I du facteur de croissance transformant bêta , Récepteur de type II du facteur de croissance transformant bêta , Transduction du signal/effets des médicaments et des substances chimiques , Protéine Smad2/métabolisme , Facteur de croissance transformant bêta-1/pharmacologie
16.
Fertil Steril ; 99(7): 1965-73.e2, 2013 Jun.
Article de Anglais | MEDLINE | ID: mdl-23472950

RÉSUMÉ

OBJECTIVE: To compare the expression of the prostaglandin (PG) E(2) transporter multidrug resistance-associated protein 4 (MRP4) in eutopic and ectopic endometrial tissue from endometriosis patients with that of control subjects and to examine whether MRP4 is regulated by the antiinflammatory lipid lipoxin A(4) (LXA(4)) in endometriotic epithelial cells. DESIGN: Molecular analysis in human samples and a cell line. SETTING: Two university hospitals and a private clinic. PATIENT(S): A total of 59 endometriosis patients and 32 age- and body mass index-matched control subjects undergoing laparoscopy or hysterectomy. INTERVENTION(S): Normal, eutopic, and ectopic endometrial biopsies as well as peritoneal fluid were obtained during surgery performed during the proliferative phase of the menstrual cycle. 12Z endometriotic epithelial cells were used for in vitro mechanistic studies. MAIN OUTCOME MEASURE(S): Tissue MRP4 mRNA levels were quantified by quantitative reverse-transcription polymerase chain reaction (qRT-PCR), and localization was analyzed with the use of immunohistochemistry. Cellular MRP4 mRNA and protein were quantified by qRT-PCR and Western blot, respectively. PGE(2) was measured in peritoneal fluid and cell supernatants using an enzyme immunoassay (EIA). RESULT(S): MRP4 was expressed in eutopic and ectopic endometrium, where it was overexpressed in peritoneal lesions and localized in the cytoplasm of glandular epithelial cells. LXA(4) attenuated MRP4 mRNA and protein levels in endometriotic epithelial cells in a dose-dependent manner, while not affecting the expression of enzymes involved in PGE(2) metabolism. Investigations employing receptor antagonists and small interfering RNA revealed that this occurred through estrogen receptor α. Accordingly, LXA(4) treatment inhibited extracellular PGE(2) release. CONCLUSION(S): We report for the first time that MRP4 is expressed in human endometrium, elevated in peritoneal endometriosis, and modulated by LXA(4) in endometriotic epithelial cells.


Sujet(s)
Endométriose/métabolisme , Endomètre/métabolisme , Cellules épithéliales/métabolisme , Lipoxines/métabolisme , Protéines associées à la multirésistance aux médicaments/métabolisme , Maladies du péritoine/métabolisme , Adulte , Liquide d'ascite/métabolisme , Biopsie , Technique de Western , Études cas-témoins , Lignée cellulaire , Dinoprostone/métabolisme , Endométriose/génétique , Endométriose/chirurgie , Endomètre/effets des médicaments et des substances chimiques , Endomètre/chirurgie , Cellules épithéliales/effets des médicaments et des substances chimiques , Antagonistes des oestrogènes/pharmacologie , Récepteur alpha des oestrogènes/antagonistes et inhibiteurs , Récepteur alpha des oestrogènes/génétique , Récepteur alpha des oestrogènes/métabolisme , Femelle , Humains , Hystérectomie , Techniques immunoenzymatiques , Immunohistochimie , Laparoscopie , Adulte d'âge moyen , Protéines associées à la multirésistance aux médicaments/génétique , Maladies du péritoine/génétique , Maladies du péritoine/chirurgie , Interférence par ARN , ARN messager/métabolisme , RT-PCR , Transfection , Régulation positive , Jeune adulte
17.
Fertil Steril ; 98(5): 1200-8, 2012 Nov.
Article de Anglais | MEDLINE | ID: mdl-22884659

RÉSUMÉ

OBJECTIVE: To analyze the expression of estrogen receptors α and ß as well as their target genes implicated in proliferation, c-myc, cyclin D1, and GREB1, in the endometrium of women with or without endometriosis. DESIGN: Expression analysis in human tissue. SETTING: University hospitals and a clinic. PATIENT(S): Ninety-one premenopausal women (59 patients with endometriosis and 32 controls) undergoing laparoscopic surgery. INTERVENTION(S): Biopsies were obtained at time of surgery, performed during the proliferative phase of the cycle. MAIN OUTCOME MEASURE(S): Estrogen receptors α and ß as well as c-myc, cyclin D1, and GREB1 mRNA expression levels were determined by quantitative reverse transcriptase-polymerase chain reaction. Tissue localization of these estrogen-regulated genes was analyzed by immunohistochemistry. RESULT(S): Estrogen receptors α and ß as well as c-myc, cyclin D1, and GREB1 mRNA expression levels were increased in ectopic tissue in comparison with both normal and eutopic endometrium. Estrogen receptor mRNA levels also were upregulated in the eutopic peritoneal tissue of patients with endometriosis. Cyclin D1 and GREB1 expression was augmented in eutopic endometrium. c-myc, cyclin D1, and GREB1 proteins exhibited a nuclear localization in ectopic endometrial tissue. CONCLUSION(S): This constitutes the first report of increased expression of GREB1, as well as cyclin D1 and c-myc, in peritoneal endometriotic lesions, implicating these proteins in estrogen-dependent growth in this context.


Sujet(s)
Prolifération cellulaire , Choristome/métabolisme , Cycline D1/analyse , Endométriose/métabolisme , Endomètre , Récepteur alpha des oestrogènes/analyse , Récepteur bêta des oestrogènes/analyse , Protéines tumorales/analyse , Maladies du péritoine/métabolisme , Protéines proto-oncogènes c-myc/analyse , Adulte , Biopsie , Études cas-témoins , Choristome/génétique , Choristome/anatomopathologie , Choristome/chirurgie , Cycline D1/génétique , Endométriose/génétique , Endométriose/anatomopathologie , Endométriose/chirurgie , Récepteur alpha des oestrogènes/génétique , Récepteur bêta des oestrogènes/génétique , Femelle , Régulation de l'expression des gènes , Allemagne , Humains , Immunohistochimie , Adulte d'âge moyen , Protéines tumorales/génétique , Maladies du péritoine/génétique , Maladies du péritoine/anatomopathologie , Maladies du péritoine/chirurgie , Protéines proto-oncogènes c-myc/génétique , ARN messager/analyse , Réaction de polymérisation en chaine en temps réel , RT-PCR , Suisse , Jeune adulte
18.
Int J Comput Assist Radiol Surg ; 7(3): 455-64, 2012 May.
Article de Anglais | MEDLINE | ID: mdl-21739112

RÉSUMÉ

PURPOSE: The aim of this work is to evaluate the potential of combining different computer-aided detection (CADe) methods to increase the actual support for radiologists of automated systems in the identification of pulmonary nodules in CT scans. METHODS: The outputs of three different CADe systems developed by researchers of the Italian MAGIC-5 collaboration were combined. The systems are: the CAMCADe (based on a Channeler-Ant-Model which segments vessel tree and nodule candidates and a neural classifier), the RGVPCADe (a Region-Growing- Volume-Plateau algorithm detects nodule candidates and a neural network reduces false positives); the VBNACADe (two dedicated procedures, based respectively on a 3D dot-enhancement algorithm and on intersections of pleura surface normals, identifies internal and juxtapleural nodules, and a Voxel-Based-Neural-Approach reduces false positives. A dedicated OsiriX plugin implemented with the Cocoa environments of MacOSX allows annotating nodules and visualizing singles and combined CADe findings. RESULTS: The combined CADe has been tested on thin slice (lower than 2 mm) CTs of the LIDC public research database and the results have been compared with those obtained by the single systems. The FROC (Free Receiver Operating Characteristic) curves show better results than the best of the single approaches. CONCLUSIONS: Has been demonstrated that the combination of different approaches offers better results than each single CADe system. A clinical validation of the combined CADe as second reader is being addressed by means of the dedicated OsiriX plugin.


Sujet(s)
Algorithmes , Tumeurs du poumon/diagnostic , , Reconnaissance automatique des formes/méthodes , Interprétation d'images radiographiques assistée par ordinateur/méthodes , Tomodensitométrie/méthodes , Diagnostic différentiel , Faux positifs , Humains , Courbe ROC , Nodule pulmonaire solitaire
19.
FASEB J ; 25(12): 4326-37, 2011 Dec.
Article de Anglais | MEDLINE | ID: mdl-21885654

RÉSUMÉ

Inflammation is intimately linked with naturally occurring remodeling events in the endometrium. Lipoxins comprise a group of short-lived, nonclassic eicosanoids possessing potent anti-inflammatory and proresolution properties. In the present study, we investigated the role of lipoxin A(4) (LXA(4)) in the endometrium and demonstrated that 15-LOX-2, an enzyme necessary for LX biosynthesis, is expressed in this tissue. Our results establish that LXA(4) possesses robust estrogenic activity through its capacity to alter ERE transcriptional activity, as well as expression of estrogen-regulated genes, alkaline phosphatase activity, and proliferation in human endometrial epithelial cells. Interestingly, LXA(4) also demonstrated antiestrogenic potential, significantly attenuating E2-induced activity. This estrogenic activity was directly mediated through estrogen receptors (ERs). Subsequent investigations determined that the actions of LXA(4) are exclusively mediated through ERα and closely mimic those of the potent estrogen 17ß-estradiol (E2). In binding assays, LXA(4) competed with E2 for ER binding, with an IC(50) of 46 nM. Furthermore, LXA(4) exhibited estrogenic activity in vivo, increasing uterine wet weight and modulating E2-regulated gene expression. These findings reveal a previously unappreciated facet of LXA(4) bioactions, implicating this lipid mediator in novel immunoendocrine crosstalk mechanisms.


Sujet(s)
Modulateurs des récepteurs des oestrogènes/métabolisme , Lipoxines/métabolisme , Phosphatase alcaline/métabolisme , Arachidonate 15-lipoxygenase/métabolisme , Séquence nucléotidique , Fixation compétitive , Lignée cellulaire , Prolifération cellulaire/effets des médicaments et des substances chimiques , Endomètre/cytologie , Endomètre/effets des médicaments et des substances chimiques , Endomètre/métabolisme , Cellules épithéliales/cytologie , Cellules épithéliales/effets des médicaments et des substances chimiques , Cellules épithéliales/métabolisme , Oestradiol/métabolisme , Modulateurs des récepteurs des oestrogènes/pharmacologie , Récepteur alpha des oestrogènes/antagonistes et inhibiteurs , Récepteur alpha des oestrogènes/génétique , Récepteur alpha des oestrogènes/métabolisme , Femelle , Humains , Lipoxines/pharmacologie , ARN messager/génétique , ARN messager/métabolisme , Petit ARN interférent/génétique , Récepteurs à hydrocarbure aromatique/antagonistes et inhibiteurs , Récepteurs à hydrocarbure aromatique/génétique , Récepteurs à hydrocarbure aromatique/métabolisme , Récepteurs aux peptides formylés/antagonistes et inhibiteurs , Récepteurs aux peptides formylés/génétique , Récepteurs aux peptides formylés/métabolisme , Récepteurs de la lipoxine/antagonistes et inhibiteurs , Récepteurs de la lipoxine/génétique , Récepteurs de la lipoxine/métabolisme , Transduction du signal
20.
J Reprod Immunol ; 92(1-2): 88-96, 2011 Dec.
Article de Anglais | MEDLINE | ID: mdl-21940052

RÉSUMÉ

Immunity and hormonal responses in the reproductive tissues of postmenopausal women are poorly understood. Secretory leukocyte protease inhibitor (SLPI), a multifunctional antimicrobial protein expressed at mucosal surfaces, is thought to play a key role in infectious and inflammatory contexts. The aim of this study was to measure SLPI production along the female reproductive tract in postmenopausal women with and without hormonal treatment. We additionally quantified estrogen receptor alpha (ERα) and progesterone receptor A (PRA) in these tissues. Expression of SLPI was decreased in the vagina and ectocervix of women under hormonal treatment. Endocervical ERα mRNA expression was increased while this did not reach significance at the protein level. SLPI expression in the endometrium was not influenced by hormonal treatment. We observed attenuated ERα expression in the cervix and endometrium of hormonally treated women, whereas vaginal expression was increased. PRA expression was augmented in the cervix and endometrium and unchanged in the vagina. Taken together, our results indicate that hormonal responses and receptor expression are differentially regulated in vaginal tissue compared with the cervix and endometrium.


Sujet(s)
Système génital de la femme/métabolisme , Hormones/métabolisme , Inhibiteur sécrétoire de la protéase leucocytaire/métabolisme , Sujet âgé , Récepteur alpha des oestrogènes/génétique , Récepteur alpha des oestrogènes/métabolisme , Oestrogénothérapie substitutive , Femelle , Analyse de profil d'expression de gènes , Régulation de l'expression des gènes , Système génital de la femme/immunologie , Système génital de la femme/anatomopathologie , Humains , Immunité muqueuse , Adulte d'âge moyen , Post-ménopause , Récepteurs à la progestérone/génétique , Récepteurs à la progestérone/métabolisme , Inhibiteur sécrétoire de la protéase leucocytaire/génétique
SÉLECTION CITATIONS
DÉTAIL DE RECHERCHE
...